BioHarvest Sciences (BHST) to showcase Botanical Synthesis at 2026 BIO Convention
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
BioHarvest Sciences Inc. filed a Form 6-K announcing it will present at the 2026 BIO International Convention in San Diego from June 22-25. The company’s session is scheduled for Wednesday, June 24 at 11:45 in Theater 3.
The presentation will highlight BioHarvest’s proprietary Botanical Synthesis™ platform, which produces plant-derived compounds with pharmaceutical-grade precision and commercial scalability. Management emphasizes recent capability expansion, increased partner engagement, and strategic initiatives aimed at collaborations with pharmaceutical and life science companies through its CDMO and nutraceutical businesses.
Positive
- None.
Negative
- None.
Key Figures
Convention dates: June 22-25
Presentation date: Wednesday, June 24
Presentation time: 11:45
+3 more
6 metrics
Convention dates
June 22-25
BIO International Convention 2026 in San Diego
Presentation date
Wednesday, June 24
Company presentation session
Presentation time
11:45
Company presentation in Theater 3
Number of BIO sessions
nearly 150 sessions
Programming at BIO International Convention
Number of BIO speakers
over 600 speakers
BIO International Convention programming
Countries represented by BIO members
more than 35 countries
Scope of Biotechnology Innovation Organization
Key Terms
Botanical Synthesis, CDMO, BIO International Convention, forward-looking statements, +1 more
5 terms
Botanical Synthesis financial
"BioHarvest Sciences’ presentation will showcase its proprietary Botanical Synthesis™ platform"
Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.
CDMO financial
"as a contract development and manufacturing organization (CDMO) on behalf of customers"
A contract development and manufacturing organization (CDMO) is a company that provides specialized services to help develop and produce pharmaceutical products for other businesses. Think of it as a contract factory that takes a company's recipe and makes the product on their behalf. For investors, CDMOs are important because they support the growth of pharmaceutical companies and can be key partners in bringing new medicines to market.
BIO International Convention financial
"it will present at the upcoming BIO International Convention, to be held on June 22-25"
forward-looking statements regulatory
"This news release contains forward-looking statements within the meaning of applicable securities laws."
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
royalties financial
"or that a developed molecule or compound will be commercialized or will generate royalties to the Company."
Payments made to the owner of an asset or intellectual property each time that asset is used or a product is sold, often calculated as a percentage of sales or a set amount per unit. Royalties matter to investors because they create predictable, ongoing income streams and affect a company’s cash flow and valuation—like a landlord collecting rent or an author getting a steady cut whenever a book is sold.
FAQ
What did BioHarvest Sciences (BHST) disclose in this Form 6-K?
BioHarvest disclosed that it will present at the 2026 BIO International Convention in San Diego. The company will showcase its Botanical Synthesis™ platform and engage with pharmaceutical and life science organizations interested in strategic collaborations and plant-based molecule development opportunities.
When and where is BioHarvest Sciences presenting at BIO 2026?
BioHarvest is scheduled to present on Wednesday, June 24 at 11:45 in Theater 3 at the BIO International Convention in San Diego. The convention runs June 22-25 and gathers global leaders from biotechnology and biopharma for partnering and industry discussions.
What is BioHarvest Sciences’ Botanical Synthesis™ platform?
Botanical Synthesis™ is BioHarvest’s proprietary platform for producing plant-derived compounds without growing the whole plant. It enables pharmaceutical-grade precision, consistency, and commercial scalability, targeting applications in drug discovery, active pharmaceutical ingredients, and next-generation therapeutics across healthcare and life science markets.
How does BioHarvest Sciences (BHST) plan to grow its business?
BioHarvest plans to grow through two verticals: CDMO services for customers seeking novel plant-based compounds and proprietary nutraceutical health and wellness products. Management highlights expanded capabilities, accelerated partner engagement, and multiple strategic initiatives aimed at long-term growth and collaboration opportunities.
How can BIO International Convention attendees meet BioHarvest Sciences?
Convention attendees can request meetings with BioHarvest via the BIO 1x1 Meeting platform. Chairman and CEO Dr. Zaki Rakib may also be available for additional meetings, and interested parties can contact the company’s communications team directly at info@bioharvest.com for further coordination.
What forward-looking risks does BioHarvest highlight for its CDMO business?
BioHarvest notes there is no assurance of additional CDMO contracts or that research agreements progress to commercialization. Increased revenue may not translate to higher profitability, and successful commercialization depends on consumer preferences, advertising budgets, and market acceptance of new plant-based products.